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Renal oxygenation defects in the spontaneously hypertensive However, Laycock et al reported that inhibition of nitric
rat: Role of AT1 receptors. oxide synthase (NOS) greatly curtails the O2 efficiency
Background. The spontaneously hypertensive rat (SHR) has for chemical work in the kidney [5]. NO can competeoxidative stress and enhanced O2 usage (QO2) relative to tubular with O2 for sites on the mitochondrial cytochrome Csodium transport (TNa). Angiotensin II (Ang II) acting on Type I
respiratory chain. This provides a mechanism wherebyreceptors (AT1-R) causes renal oxidative stress and functional
nitric oxide (NO) deficiency that could enhance O2 usage. NO may regulate QO2 [6, 7].
Therefore, we investigated the hypothesis that AT1-Rs mediate The spontaneously hypertensive rat (SHR) kidney has
the inefficient renal oxygenation in the SHR.
evidence of functional NO deficiency that can be ascribedMethods. Groups of SHR and WKY received vehicle (Veh),
to oxidative stress [8]. In this SHR model we found thatcandesartan (Cand) or hydralazine  hydrochlorothiazide 
reserpine (HHR) for two weeks. there was indeed a substantially lower pO2 in the kidney,
Results. Compared to WKY  Veh, the elevated BP of compared to the Wistar Kyoto (WKY) rat that was as-
SHR  Veh (153  3 vs 115  3 mm Hg; P  0.001) was cribed to a reduction in the O2 efficiency for Na trans-normalized by Cand (117  4) or HHR (113  5 mm Hg).
port (TNa:QO2) [3]. Renal NO activity in the juxtaglomeru-The reduced renal blood flow of SHR  Veh (2.4  0.3 vs.
4.1  0.3 mL · min1 · 100 g1) was increased (P  0.05) by lar apparatus of the SHR is reduced. This can be
Cand (3.6  0.3) and HHR (3.2  0.2). Compared to WKY  corrected by an angiotensin II (Ang II) type 1 receptor
Veh, SHR  Veh had a 50% reduction in TNa:QO2 (16.9  2.0 (AT1-R) antagonist, candesartan (Cand), but not by non-vs. 7.8  0.9 mol: mol1, P  0.01) that was unchanged by
specific anti-hypertensive therapy with hydralazine, hy-HHR (8.6  1.1), but was increased by Cand (13.2  1.4; P 
drochlorothiazide and reserpine (HHR) [9]. Therefore,0.01). The pO2 of outer cortex was lower in SHR  Veh than
WKY  Veh (31  3 vs. 41  2 mm Hg; P  0.05) and it was the present series were designed to test the hypothesis
not changed significantly by HHR (37 2) but was normalized that the defects in renal oxygenation in the SHR kidney
by Cand (44 3 mm Hg; P 0.01). The pO2 in the deep cortex are due to AT1-R activation.also was lower in SHR  Veh than WKY  Veh (18  3 vs.
30  3 mm Hg; P  0.005) and was not changed significantly
by HHR (19  2), but was increased by Cand (25  3 mm Hg;
METHODSP  0.05).
Conclusions. The reduced pO2 in outer and inner cortex, Experiments were approved by the Georgetown Uni-
and inefficient utilization of O2 for Na transport in the SHR versity Animal Care and Use Committee, and performed
kidney can be ascribed to the effects of AT1-R, largely indepen- according to the NIH guidelines for the conduct of exper-dent of blood pressure.
iments in animals. Studies were performed on male
SHRs and control WKY rats age 8 to 10 weeks obtained
from Harlan-Sprague-Dawley (Madison, WI, USA). RatsThere is normally a direct relationship in the kidney
were maintained on standard rat chow (Ralston-Purina,between oxygen usage (QO2) above basal levels and the St Louis, MO, USA) with a sodium content of 0.3 g ·
chemical work for tubular sodium transport (TNa) [1–4]. 100 g1. They were allowed free access to food and water
until the day of study.
Key words: hypertension, candesartan, oxidative stress, nitric oxide,
Animal preparationangiotensin II, angiotensin receptor blocker (ARB).
Groups of SHR and age-matched WKY rats were pre-Received for publication April 15, 2002
pared for in vivo clearance and micropuncture studiesand in revised form June 24, 2002
Accepted for publication August 28, 2002 as described in detail previously [10]. In brief, animals
were anesthetized with thiobarbital (Inactin, 100 mg · 2003 by the International Society of Nephrology
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kg1 IP; Research Biochemicals, Inc., Natick, MA, USA). blood samples were measured by both a blood gas ana-
lyzer (BGA) and the electrode, in random order. TheA catheter was placed in a jugular vein for fluid infusion
and in a femoral artery for the recording of mean arterial pO2 measured by each method was similar (BGA 
81.4  1.6 vs. electrode  79.2  1.3; NS).pressure (MAP) from the electrically-damped output of
a pressure transducer (Statham, Inc., Oxnard, CA). A
Calculation of parameters of kidney function andtracheotomy tube was inserted. The animals were allowed
kidney O2 usageto breathe room air spontaneously. A catheter was placed
in the bladder to collect urine. The left kidney was exposed The O2 content of systemic arterial and renal venous
blood was measured in a co-oximeter (Model 682; Instru-by a flank incision, cleaned of connective tissue, and stabi-
lized in a Lucite cup. It was bathed in 0.154 mol/L NaCl mentation Lab, Lexington, MA, USA) from blood sam-
ples drawn from the femoral artery cannula and theequilibrated with air and maintained at 37C. After com-
pletion of surgery, rats were infused with a solution of renal vein [3]. The glomerular filtration rate (GFR) was
calculated from the clearance of [3H]-inulin. The renal0.154 mol/L NaCl and 1% albumin at 1.5 mL · h1 to
maintain euvolemia [10]. Studies were begun after 60 plasma flow (RPF) was calculated from the clearance of
[3H]-inulin corrected for the measured renal extractionminutes for stabilization.
of [3H]-inulin [14]. The renal blood flow (RBF) was calcu-
Measurement of renal clearance lated from the RPF factored by 1-hematocrit (Hct). The
net tubular transport of sodium (TNa) was calculated fromFor clearance, [3H]-inulin (0.1 Ci · mL1; ICN Bio-
chemicals, Costa Mesa, CA, USA) was added to the IV the difference between the filtered load of sodium (calcu-
lated from the product of the GFR and plasma sodiumfluid infusion. Urine was obtained from the bladder. The
study period lasted 60 minutes during which a single concentration [PNa]) and the renal sodium excretion
(UNaV). Net renal oxygen usage (QO2) was calculatedrenal clearance was undertaken. Values of MAP and
heart rate (HR) were obtained over 15 minute intervals from the product of RBF and arteriovenous (A-V) O2.
and averaged. Blood (200 L) was drawn from the femo- The measurements of renal venous O2 content (RVO2)
ral artery and renal vein at the end of the study for 3H were made in the renal vein after it had exited from the
and pO2 measurements. Renal venous blood was ob- kidney. Therefore, this measure of renal O2 usage is not
tained using a # 23 gauge steel needle inserted into the confounded by the presence of any A-V shunt for O2
renal vein and angled toward the kidney. Samples for within the kidney [3, 15]. The oxygen efficiency for Na
pO2 were capped and kept on ice until they were mea- transport was calculated from the ratio of TNa:QO2.
sured, after minimal delay, in a Corning Blood Gas Ana-
lyzer (Model 525; Boston, MA, USA). Protocols
For 14 to 18 days, groups of SHR (N  8 to 10) andMeasurements of intra-nephronal and tissue pO2 WKY (N  4 to 8) rats received a daily gavage with
These measurements were made on groups of SHR vehicle (Veh), candesartan (Cand; 3 mg · kg1 · day1) or
and WKY that were separate from those used for the hydralazine  hydrochlorothiazide  reserpine (HHR;
clearance studies but followed an identical protocol. 30  10  0.2 mg · kg1 · day1). Drugs were withheld
Studies for nephron and tissue pO2 utilized a custom- on the day of study.
designed and validated ultramicro, coaxial, recessed-
tipped, platinum glass micro-needle electrode [11–13]. Drugs
The outer tip diameter was 3 to 5 m. It was coated Candesartan cilexetil was a gift from Peter Morsing,
with an O2-permeable membrane by dipping it in collo- Ph.D., of AstraZeneca Inc. (Mondal, Sweden). Other
dion and polystyrene. This electrode could be inserted drugs were obtained from Sigma (St. Louis, MO, USA).
into superficial tubules without obstructing flow or dam-
aging local blood supply to measure the intra-luminal Statistical methods
pO2. The membranized recessed tip allows the measure- Values are reported as mean  SE. A repeated mea-
ment of pO2 in flowing solutions in vivo with an error sures analysis of variance (ANOVA) was applied to data
of 1.5% (stirring effect) [3]. of SHR and WKY administered vehicle, candesartan, or
The electrode was connected to an ultra high im- HHR. Where appropriate, a post-hoc Dunnett’s t test
pedence picoammeter (pA6000; WPI, Sarasota, FL, was applied thereafter. Values are taken as statistically
USA). The output was subjected to analog-digital con- significant if P  0.05.
version and displayed on a computer (Mac-lab 4A; AD-
Instruments, Castle Hill, Australia). This system pro-
RESULTSvides a very rapid, stable and linear output in response
to pO2 across the tested range of 4 to 500 mm Hg [3]. The data for body weight, MAP, hematocrit (Hct) and
whole kidney function in the six groups of rats are shownTo validate the accuracy of the electrode, six arterial
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Table 1. Body weight, blood pressure, hematocrit and renal function
GFR RBF
Body weight MAP Hct Urine flow
Group g mm Hg % lL · min1 mL · min1 · 100 g BW1
1. WKY  Veh (N  8) 25516 1153 441 5.30.6 0.630.03 4.10.3
2. WKY  HHR (N  4) 27612 1102 441 5.60.5 0.720.05 4.50.4
P vs. #1 NS NS NS NS NS NS
3. WKY  Cand (N  4) 26610 1094 451 6.40.6 0.710.05 4.20.4
P vs. #1 NS NS NS NS NS NS
4. SHR  Veh (N  11) 2469 1533 471 3.60.4 0.410.04 2.40.3
P vs. #1 NS 0.01 NS 0.05 0.05 0.01
5. SHR  HHR (N  7) 2509 1135 441 5.10.8 0.500.04 3.20.2
P vs. #4 NS 0.01 NS NS NS 0.05
6. SHR  Cand (N  8) 2535 1174 451 5.30.5 0.600.07 3.60.3
P vs. #4 NS 0.01 NS 0.05 0.05 0.05
Mean  SEM values (N  number of rats). Abbreviations are: Veh, vehicle; Cand, candesartan; HHR, hydralazine, hydrochlorothiazide and reserpine.
in Table 1. The MAP was 38 mm Hg higher in SHR. It 0.63, P  0.01) was significantly higher (P  0.05) with
a similar intercept. Figure 2A demonstrates that the indi-was reduced similarly and to values of WKY by HHR
and Cand. Urine flow (UV) under anesthesia was lower vidual values for SHR  HHR tended to fall below the
line for SHR  Veh. There was a significant regressionin SHR  Veh compared to WKY  Veh, and was in-
creased significantly in SHR given Cand. The GFR, RPF for SHR  HHR (y  0.08x  4.04; r  0.74, P  0.01).
However, the slope was not significantly different fromand RBF were lower in SHR, compared to WKY as in
previous series [8]. The GFR was not affected signifi- corresponding values for SHRVeh. Figure 2B demon-
strates that the individual values for SHR  Cand werecantly in either strain by HHR or Cand, but the RBF
was increased significantly in SHR given Cand or HHR. uniformly well below those for SHR  Veh. There was
a significant regression for SHR  Cand (y  0.05x Parameters for whole kidney oxygen delivery and us-
age are related to tubular sodium transport and oxygen 2.89; r  0.61, P  0.01). The slope of this regression
was significantly (P  0.05) below that for SHR  Vehefficiency in Table 2. As in a previous series [8], SHR 
Veh, compared to equivalent WKY, had a reduced O2 and was not different from WKY  Veh.
delivery due to a reduced RBF. The O2 delivery was Groups of SHR were given vehicle (N 7), Cand (N
increased significantly in SHR by Cand and HHR due 7) or HHR (N  8) and groups of WKY were given
to the increase in RBF. Despite the reduced O2 delivery, vehicle (N  6), Cand (N  5) and HHR (N  4) for
renal O2 usage was maintained in the SHR  Veh due study with an ultramicro O2 electrode to measure the
to a large increase in the arteriovenous difference for pO2 in the renal cortex. As shown in Table 3, the pO2
O2 across the kidney. O2 usage was not affected by Cand values in SHR  Veh were consistently below those of
or HHR. Tubular sodium transport was reduced in the WKY  Veh. Neither Cand nor HHR affected the pO2
SHRVeh in parallel with a reduced GFR. Administra- values in WKY (data not shown). As shown in Figure 3,
tion of HHR or Cand to WKY or of HHR to SHR did the values of pO2 of SHR administered vehicle were
not affect TNa significantly. In contrast, administration of similar in proximal tubules and outer cortex (PT, 31  2
Cand to SHR increased TNa significantly in parallel with and OC, 31  3 mm Hg), but were reduced by 42% in
the increase in GFR. the deep cortex (DC, 18 3 mm Hg). These parameters
The oxygen efficiency for sodium transport (TNa:QO2) in SHR were not affected by HHR. In contrast, Cand
for the six groups of rats is shown in Figure 1. It is apparent increased the pO2 significantly at each site in the SHR
that the oxygen efficiency was reduced (P  0.01) by to values that were not significantly different from those
46% in vehicle treated SHR, compared to equivalent recorded in WKY  Veh.
WKY. HHR did not significantly modify the efficiency
in either strain. Cand did not modify the efficiency in
DISCUSSIONWKY, but increased it significantly in SHR to values not
Our previous study showed that the kidney cortex ofsignificantly different from vehicle-infused WKY.
the SHR is hypoxic compared to the WKY. The mainThe individual values for oxygen usage as a function
new findings in our current study are that two weeks ofof sodium transport are shown in Figure 2. We had dem-
administration of an ARB corrects fully the reduced pO2onstrated previously that there is a significant correlation
between these parameters in vehicle infused WKY (y  in the outer and inner cortices of the SHR and reverses
the inefficient use of O2 for Na transport. In contrast,0.048x  3.3; r  0.65, P  0.01) [3]. The slope of the
relationship in SHR  vehicle (y  0.10x  4.52; r  HHR did not alter these variables significantly. Both
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Fig. 1. Ratio of renal sodium transport to renal oxygen usage in control
WKY and hypertensive SHR rats treated for two weeks with vehicle
hydrochlorothiazide, hydralazine and reserpine (HHR) or candesartan
for two weeks. Values are mean  SEM. *P  0.01 compared to WKY
given vehicle.
treatments had comparable effects to lower BP and to
increase RBF in the SHR.
These studies confirm the tight relationship in the kid-
ney between O2 usage and tubular Na transport above
a basal level [1–4, 16, 17]. This relationship holds during
changes in O2 delivery produced by aortic clamping, or
changes in Na load and transport produced by infusion
of hypertonic NaCl solution or diuretic drugs [1, 2, 4,
18]. However, a decrease in O2 efficiency occurs during
infusion of mannitol, which had been related to the back
flux of reabsorbed Na across the permeable proximal
tubule segments [19]. The SHR is a model of renal oxida-
tive stress [8], which can compromise the integrity of the
tight junction of confluent cultures of proximal tubule
cells [20]. Therefore, one explanation for the reduced
O2 efficiency for Na transport in the hypertensive kid-
ney, and its correction by an ARB, could be an effect
of reactive oxygen species (ROS) to enhance back flux
of reabsorbed NaCl and fluid. However, increased back
flux of reabsorbed Na cannot be a sole explanation for
the decreased O2 efficiency of the SHR kidney, because
O2 usage in a suspension of renal cortical tubules studied
ex vivo is increased 15 to 25% in the SHR where there
is no back flux of Na [21]. This observation also makes
it unlikely that the reduced efficiency can be ascribed
solely to the immediate effects of renal hemodynamics,
renal nerves or circulating factors.
Reactive oxygen stress, notably H2O2, can inhibit
Na,K-ATPase in cardiac or kidney cells, independent
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of NO [22]. Moreover, inhibition of Na,K-ATPase
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Fig. 2. Individual values for renal oxygen usage as a function of tubular sodium transport in SHR kidneys. (A ) Compares SHR given vehicle (;
N  11) with SHR given hydrochlorothiazide, hydralazine and reserpine (HHR; ; N  7). The regression for the SHR  vehicle is given by: y 
0.1x  4.52; r  0.63; P  0.01. The regression for SHR given HHR is: y  0.08x  4.04; r  0.742; (P  0.001). (B ) Compares values for SHR
given vehicle (; N  11) with SHR given candesartan (; N  8). The regression for SHR  Cand is: y  0.05x  2.89; r  0.613; P  0.01.
Table 3. Comparison of pO2 measured in the renal cortex of WKY
and SHR given vehicle
pO2 mm Hg
Strain PT DT OC IC
WKY (N  6) 423 392 412 303
SHR (N  7) 312 322 313 183
P value 0.01 0.05 0.05 0.05
Values are meanSEM; N  number of rats studied.
generates oxidative stress [23], providing for a positive
amplification. Therefore, a second possible cause of re-
duced TNa:QO2 in the kidney of the SHR could be that
oxidative stress impairs TNa via inhibition of Na,K-
ATPase activity. However, correction of oxidative stress
with a permeant superoxide dismutase (SOD) mimetic Fig. 3. Partial pressure of oxygen in the SHR kidney. Values are mean
SEM for the intraluminal recording from the proximal tubule, interstitialin dogs inhibits TNa via an NO-independent process (ab-
recording from the superficial outer cortex and recording from the innerstract; Majid SA et al, J Am Soc Nephrol 11:337A, 2000).
cortex of rats treated for two weeks with vehicle, hydrochlorothiazide,
The relatively low pO2 of the renal cortex compared hydralazine and reserpine (HHR) or candesartan. Compared to vehicle
treatment, *P  0.05, **P  0.01.to the high rate of renal blood flow has been attributed
both to the high rate of chemical work for tubular Na
transport, and to a diffusional shunt for O2 before the renal
parenchyma [3, 15]. The reduced pO2 in the renal cortex for a low TNa:QO2 during oxidative stress may be that O2
·
of the SHR has been related to inefficient utilization of inactivates NO, thereby uncoupling cellular respiration.
O2 for Na transport [3]. This parameter is an integrative This is consistent with the finding of Laycock et al [5]
effect of many metabolically diverse cell types within that inhibition of NO production in the dog with nitro
the kidney. Recent studies have shown that NO can l-arginine doubled the renal O2 usage relative to TNa.
compete with O2 for the mitochondrial cytochrome-C This was due to a reduction in the GFR, thereby reducing
respiratory chain and thereby set the level of cellular TNa, and an increase in the A-V oxygen gradient across
the kidney, thereby increasing QO2. These results arerespiration [6, 7]. Therefore, a third possible explanation
Welch et al: AT1 receptors and renal oxygenation 207
reminiscent of our findings in the kidney of vehicle-infused In conclusion, the low renal cortical pO2, and ineffi-
cient utilization of O2 for TNa in the kidney of the SHRSHR where there is also a reduced TNa and increased
(A-V) O2 gradient (Table 2). can be reversed by prolonged administration of an ARB.
These effects appear to be largely independent of theThe cortex of the SHR kidney has been characterized
as a site of functional NO deficiency [8, 24, 25] that can fall in blood pressure.
be related to oxidative stress, since it is reversed by an
SOD mimetic, tempol [8]. Candesartan, but not HHR, ACKNOWLEDGMENTS
can restore a normal NO bioactivity in the SHR, and These studies were supported by the National Institute of Diabetes,
prevent a response to tempol, which implies that cande- Digestive, and Kidney Diseases grant (DK-36079 and DK-49870), the
National Institute for Heart, Lung and Blood (HL68686-01), and fundssartan reverses oxidative stress [9]. Therefore, a third
from the George E. Shreiner Chair of Nephrology. We are gratefulpossible explanation for our results is that they represent to Ms. Sharon Clements for preparing the manuscript.
the effects of a reduction in NO bioavailability in the
SHR kidney due to oxidative stress that is corrected by
APPENDIXcandesartan.
The source of oxidative stress in the SHR kidney may Abbreviations used in this article are: Ang II, angiotensin II; ACEI,
angiotensin converting enzyme inhibitor; ARB, angiotensin receptorbe an enhanced expression of the p47phox regulatory compo-
blocker; AT1, angiotensin type I; AT1-R angiotensin II, type I receptor;nent of nicotine adenine dinucleotide phosphate (NADPH)
Cand, Candesartan; GFR, glomerular filtration rate; Hct, hematocrit;
oxidase [26]. The p47phox is expressed with other compo- HHR, hydralazine hydrochlorothiazide reserpine; HR, heart rate;
JGA, juxtaglomerular apparatus; MAP, mean arterial pressure; MD,nents of NADPH oxidase on the luminal border of the
macula densa; 7-NI, 7-nitroindazole; NO, nitric oxide; NOS, nitricmacula densa, the adjacent cortical thick ascending limb
oxide synthase; PNa, plasma sodium concentration; QO2, renal oxygencells, the distal tubule and the collecting ducts, as well usage; RBF, renal blood flow; RVR, renal vascular resistance; RPF,
as on interstitial fibroblasts, blood vessels and glomerular renal plasma flow; O2·, oxygen radical; SHR, spontaneously hyperten-
sive rat; SOD, superoxide dismutase; TGF, tubuloglomerular feedback;podocytes. Therefore, it is widely expressed in the renal cor-
TNa, tubular sodium transport; Veh, vehicle; WKY, Wistar Kyoto rat.tex and could be a source of enhanced generation of O2·.
A limitation of these studies is that they have been Reprint requests to Christopher S. Wilcox, M.D., Ph.D., Division of
Nephrology and Hypertension, Georgetown University Medical Center,performed under anesthesia. This stress will have acti-
3800 Reservoir Road, NW, PHC Suite #F6003, Washington, D.C. 20007-vated the sympathetic nervous system and thereby in-
2197, USA.
fluenced the renal function and the response to angioten- E-mail: wilcoxch@georgetown.edu
sin blockade. This may be important because the SHR
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